APR 05, 2017 07:15 AM PDT

Optimizing homology-directed repair (HDR) results with CRISPR-Cas9

Speakers
  • Research Scientist at Dharmacon, part of GE Healthcare
    Biography
      John Schiel is a research scientist at Dharmacon, part of GE Healthcare. He joined the R&D team at Dharmacon in 2014 and is actively involved in developing research tools within the gene modulation and genome editing fields of research which include RNA interference (http://dharmacon.gelifesciences.com/rnai-and-custom-rna-synthesis/) and CRISPR-Cas9 genome engineering (http://dharmacon.gelifesciences.com/gene-editing/crispr-cas9/) He received his Bachelor of Science degree in Biochemistry at Colorado State University and his Ph.D. degree in Cell Biology at the University of Colorado Denver - Anschutz Medical Campus. John completed a postdoctoral fellowship at University of Massachusetts Medical School where he studied asymmetric cell division and centrosome maturation.

    Abstract:

    CRISPR-Cas9 has increased the accessibility of genome engineering due to its ease of use and ability to cause double strand breaks (DSBs) at almost any locus of interest. DSBs are repaired in cells by two predominant pathways: non-homologous end joining (NHEJ) and homology-directed repair (HDR). Endogenous repair of DSBs using the NHEJ pathway typically results in functional protein disruption (knockout) whereas the HDR pathway can be used to introduce exogenous genetic content (knockin). During this webinar we will focus on the utility of a synthetic dual RNA approach to apply CRISPR-Cas9 to HDR genomic engineering applications and will provide guidelines for improving CRISPR Cas9-assisted HDR. We will also discuss the use of short single-stranded DNA as a donor template for small insertions as well as plasmid DNA donor templates for large insertions. Lastly, we outline methods for characterization of HDR-generated cell lines for precise genomic engineering.


    Show Resources
    You May Also Like
    AUG 27, 2019 09:00 AM PDT
    C.E. CREDITS
    AUG 27, 2019 09:00 AM PDT
    DATE: August 27, 2019 TIME: 9:00am PDT, 12:00pm EDT Immunotherapies targeting PD-1 or PD-L1 have proven remarkably effective for treating cancer in some patients, with considerabl...
    JUN 05, 2019 05:00 PM CEST
    C.E. CREDITS
    JUN 05, 2019 05:00 PM CEST
    DATE: June 5, 2019TIME: 8:00am PDT, 11:00am EDT, 5:00pm CEST Eukaryotic cell cultures respond to the most subtle influence. Apart from the risk of contamination, minimal chan...
    OCT 02, 2019 11:00 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    OCT 02, 2019 11:00 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    DATE: October 2, 2019TIME: 11:00am PDT, 2:00pm EDT Ditch the Excel spreadsheets and manage your molecular workflows entirely in your LIMS Achieve configuration of molecular workf...
    SEP 05, 2019 04:00 PM CEST
    C.E. CREDITS
    SEP 05, 2019 04:00 PM CEST
    DATE: September 5, 2019TIME: 7:00am PT, 10:00am ET, 4:00pm CEST PCR (Polymerase Chain Reaction) has gone through a massive evolution since its development in 1983. Besides it...
    MAY 21, 2019 07:00 AM PDT
    C.E. CREDITS
    MAY 21, 2019 07:00 AM PDT
    DATE: May 21, 2019TIMEL 7:00am PT, 10:00am ET Human T cells are central effectors of immunity and cancer immunotherapy. CRISPR-based functional studies in T cells could prioriti...
    MAY 16, 2019 04:00 PM CEST
    C.E. CREDITS
    MAY 16, 2019 04:00 PM CEST
    DATE: May 16, 2019TIME: 7:00am PDT, 10:00am EDT, 4:00pm CEST The emergence of NGS is revolutionizing the microbiological sciences and transforming medicine. Deep sequencing has...
    Loading Comments...
    Show Resources